anti sars cov 2 spike s1 protein antibody  (Novus Biologicals)

Journal: Viruses

Article Title: Insertion in the N-Terminal Domain of the SARS-CoV-2 Spike Glycoprotein Affects Antibody Recognition and Phenotypic Properties

doi: 10.3390/v18030277

Figure Lengend Snippet: ( A ) Linearized region of the SARS-CoV-2 genome encoding the spike glycoprotein. The spike glycoprotein is divided into two subunits (S1 and S2). The S1 subunit contains two subdomains (SD1 and SD2), as well as a receptor-binding domain (RBD) and an N-terminal domain (NTD). The location of the KRTRS insertion is marked with an arrow in the NTD region of the spike glycoprotein in the Delta s.p. variant of the virus; ( B ) overall 3D structure of the trimer, whose monomers are spike glycoproteins. The 3 NTD regions of each monomer are marked in red. The NTD of one of the monomers is shown separately, with the KRTRS insertion region in the Delta s.p. variant marked in cyan. The RCSB Protein Data Bank IDs for the SARS-CoV-2 spike protein structures is 6ZGG, the visualization was made using UCSF chimera—1.19.

Article Snippet: Primary antibodies were added and incubated for 1 h at 37 °C: a monoclonal antibody against the SARS-CoV-2 spike protein (2 mg/mL; 1:2500; FSASI “Chumakov FSC R&D IBP RAS” (Institute of poliomyelitis), Moscow, Russia), polyclonal antibody against SARS-CoV-2 spike protein (600-401-MS9, Rockland, NY, USA) and a polyclonal antibody against the N protein (1 mg/mL, 1:500; FSASI “Chumakov FSC R&D IBP RAS” (Institute of poliomyelitis), Moscow, Russia).

Techniques: Binding Assay, Variant Assay, Virus

Journal: Viruses

Article Title: Insertion in the N-Terminal Domain of the SARS-CoV-2 Spike Glycoprotein Affects Antibody Recognition and Phenotypic Properties

doi: 10.3390/v18030277

Figure Lengend Snippet: ELISA with: ( A ) polyclonal antibodies to the spike glycoprotein of SARS-CoV-2 virus; ( B ) monoclonal recombinant antibodies to the spike glycoprotein of SARS-CoV-2 virus; ( C ) polyclonal antibodies to the N (nucleocapsid) protein of SARS-CoV-2 virus. The antigen was subjected to titration by threefold serial dilution, beginning with the stock concentration. Dilution factors are presented as logarithms to the base 3 (log 3 ). The dotted line indicates the background signal determined from wells without virus coating (negative control). All data are presented as averages with standard deviation * p < 0.05, *** p < 0.001, **** p < 0.0001 according to the multiple comparisons for two-way ANOVA using GraphPad Prism 8.2.1. Columns in the chart with a “ns” indicate that the observed differences between the variables are not statistically significant.

Article Snippet: Primary antibodies were added and incubated for 1 h at 37 °C: a monoclonal antibody against the SARS-CoV-2 spike protein (2 mg/mL; 1:2500; FSASI “Chumakov FSC R&D IBP RAS” (Institute of poliomyelitis), Moscow, Russia), polyclonal antibody against SARS-CoV-2 spike protein (600-401-MS9, Rockland, NY, USA) and a polyclonal antibody against the N protein (1 mg/mL, 1:500; FSASI “Chumakov FSC R&D IBP RAS” (Institute of poliomyelitis), Moscow, Russia).

Techniques: Enzyme-linked Immunosorbent Assay, Virus, Recombinant, Titration, Serial Dilution, Concentration Assay, Negative Control, Standard Deviation